Furthermore, based on our present data, KAT2B could be studied as a biomarker with even higher potential to predict the therapeutic effect of olaparib treatment in CRC patients regardless of whether the patients harbor intrinsic BRCA-mutations or not and independent of mutational or molecular patterns suggesting BRCA-ness. The gene discussed is KAT2B; the disease is colorectal carcinoma.